Ritlecitinib

Overview

Ritlecitinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL4085457).

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Ritlecitinib expires 17 Oct 2041 and exclusivity 23 Jun 2028. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one

Canonical SMILES

C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3

InChIKey

CBRJPFGIXUFMTM-WDEREUQCSA-N